ADRO Aduro Biotech Inc.

4.09
+0.01  (+0%)
Previous Close 4.08
Open 4.08
Price To Book 2.06
Market Cap 324762704
Shares 79,404,084
Volume 1,496,694
Short Ratio
Av. Daily Volume 1,014,145

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 initiation announced December 18, 2017.
BION-1301
Multiple Myeloma
Initial data at SITC November 2018 noted 2/40 PRs and 11 with SD.
ADU-S100
Solid tumors or lymphomas
Phase 2b primary endpoint not met - May 2016
CRS-207 and GVAX Pancreas - ECLIPSE trial
Pancreatic cancer
Partial clinical hold announced October 24, 2016. Hold released November 21, 2016.
CRS-207 and GVAX Pancreas and nivolumab - STELLAR trial
Pancreatic cancer
Noted December 12, 2017 that development to be discontinued.
CRS-207 with pembrolizumab
Mesothelioma - cancer
Phase 1 ongoing.
pLADD
Colorectal Cancer
Phase 1 ongoing.
pLADD
Colorectal Cancer
Phase 1b initiation announced June 7, 2018.
ADU-214 with Nivolumab
Non-Small Cell Lung Cancer
Phase 1 dose escalation data due 2H 2019.
ADU-S100 and Spartalizumab
Solid tumors or lymphomas
Phase 1 commencement of dosing announced February 11, 2019.
ADU-S100 and ipilimumab
Melanoma

Latest News

  1. What's in Store for Vericel (VCEL) This Earnings Season?
  2. Will Difficult Comparison Hurt Bio-Rad's (BIO) Q4 Earnings?
  3. Aduro Biotech to Present at the 8th Annual SVB Leerink Global Healthcare Conference
  4. Aduro Announces Changes to its Board of Directors
  5. Will Hospice Strength Show on Amedisys' (AMED) Q4 Earnings?
  6. What's in Store for Tandem Diabetes' (TNDM) Q4 Earnings?
  7. What's in Store for Sangamo (SGMO) This Earnings Season?
  8. The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna
  9. Consolidated Research: 2019 Summary Expectations for The Trade Desk, Aduro Biotech, Walker & Dunlop, California Resources, Century Casinos, and Arsanis — Fundamental Analysis, Key Performance Indications
  10. Will Aduro Biotech Continue to Surge Higher?
  11. 5 Tiny Biotech Stocks With Superb Growth Potential
  12. Aduro Initiates Dosing in Phase I Melanoma Study on ADU-S100
  13. Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?
  14. Merrimack (MACK) Stock Up Year to Date: Is a Rebound Likely?
  15. Aduro Announces First Patient Dosed in Phase 1 Study of ADU-S100 (MIW815) in Combination with YERVOY (ipilimumab) for the Treatment of Relapsed and Refractory Melanoma
  16. AMAG Q4 Loss Narrower Than Expected, Revenues Lag Estimates
  17. Top Ranked Momentum Stocks to Buy for February 6th
  18. Why are deep-pocketed biotechs cutting hundreds of jobs?